Research, Consulting and Supply Agreements	9 Months Ended
Sep. 30, 2021
Research Consulting And Supply Agreements
Research, Consulting and Supply Agreements	Note 15: Research, Consulting and Supply Agreements In July 2021, the Company executed a Reservation and Start-Up Agreement (the “Agreement”) with hVIVO Services Limited (“hVIVO”), and subsequently signed a clinical trial agreement (“CTA”) in September. The Company has paid hVIVO approximately $672,000, representing half of the booking fee for use of its quarantine facility. The balance of the agreement is approximately $3,398,000. In January 2021, the Company entered into a Sponsor Agreement with the Centre for Human Drug Research (“CHDR”) for a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as a potential intranasal therapy. The Company has paid CHDR approximately $1,010,000. The balance of the agreement is approximately $70,000.

Research, Consulting and Supply Agreements

9 Months Ended

Sep. 30, 2021

Research Consulting And Supply Agreements

Research, Consulting and Supply Agreements

Note 15: Research, Consulting and Supply Agreements

In July 2021, the Company executed a Reservation and Start-Up Agreement (the “Agreement”) with hVIVO Services Limited (“hVIVO”), and subsequently signed a clinical trial agreement (“CTA”) in September. The Company has paid hVIVO approximately $672,000, representing half of the booking fee for use of its quarantine facility. The balance of the agreement is approximately $3,398,000.

In January 2021, the Company entered into a Sponsor Agreement with the Centre for Human Drug Research (“CHDR”) for a Phase 1 clinical study to assess the safety, tolerability, and biological activity of Ampligen as a potential intranasal therapy. The Company has paid CHDR approximately $1,010,000. The balance of the agreement is approximately $70,000.